Abstract
Author presented a revue of actual informations on immunooncologic (IO) therapy of non small cell lung cancer. The indication rules of nivolumab, pembrolizumab, atezolizumab and durvalumab are presented.
First line imunotherapy with the use of pembrolizumab should be given in PD-L1 high expression cancer cells of NSCLC. The results of clinical studies concerning combinations of chemoimunotherapy and chemotherapy, imunotherapy and antiangiogenic therapy are also presented.
In locally advanced NSCLC, concomitant chemoradiotherapy should be followed by IO therapy with durvalumab. Combination of IO treatment, chemotherapy and antiangiogenic therapy should be benefitial also in patients with EGFR/ALK driven cancers after the failure of targeted therapy, as well as in patients with advanced NSCLC and initialy confirmed liver metastatic lesions.
IO therapy nowadays changes the guidelines of NSCLC therapeutic options.